Siddharth Velmankar · Chief Product Officer · India
| Capacity | Committees |
|---|---|
| Ready to join | A product, customer or technology committee where healthcare-workflow experience fits the mandate after induction and assessment |
I would consider a first appointment in healthcare-workflow equipment or a related product-and-service business where the board wants a clearer view of the conditions inside its customer promise. The company’s stage, portfolio and existing skills would determine whether my experience adds enough. Product or customer committee work might be relevant after preparation, but it remains an interest to assess rather than a position I can claim in advance.
My career offers a movement from packaging-task analysis to portfolio choices involving physical fit and installation. It includes an owned prototype error and outcomes that remained incomplete or limited to particular sites. I would expect the nomination discussion to test those examples for applicability, not simply accept the seniority of the final title. The intended next step is a considered part in collective oversight, with preparation, suitability, independence and appointment resolved through the company’s proper enquiry.
IICA Independent Directors’ Databank: Not yet registered
The fictional record contains no registration in India’s Independent Directors’ Databank and no exemption claim. The relevant eligibility, registration and preparation requirements would need to be checked for a proposed appointment.
I would help a healthcare-equipment board examine whether the company’s product account includes the conditions that make its offer useful in the customer’s workplace. A feature can be present while the equipment does not fit the available space. A standard bundle can be comprehensive while a particular site needs only part of it. A dispatch can be complete while installation remains pending. Those distinctions can affect the promise management is making and the evidence directors need to understand it.
My experience is grounded in a defined executive function. At Pravellen I lead ninety-six product colleagues through six direct reports with ₹31 crore delegated FY 2026–27 expense. Engineering, clinical assessment, quality and regulatory work, manufacturing, service, sales and finance retain separate responsibilities. I would bring experience of product decisions made with those colleagues, while remaining clear that the title does not confer each specialist competence or make a product observation a clinical conclusion.
Executive presentations since July 2021 are my existing exposure to the board. The fictional record contains no statutory appointment. A first seat would require preparation for collective responsibilities and the company’s particular circumstances. I would want my own outer-carton error considered alongside the more recent portfolio decisions, because oversight benefits from a realistic account of how judgement can be challenged and corrected. The contribution is a way of questioning the offer, not a claim that every institution should adopt Pravellen’s chosen configuration.
Presented to the Board or a committee
Executive presentations on equipment propositions, workplace fit and installation dependencies
July 2021 — present
Presented product scope and bounded pilot findings as CPO; no statutory-director or board-committee appointment in the invented chronology.
The workstation proposal measured 750 millimetres deep, while thirty-one of forty-two laboratories had available depth of six hundred millimetres or less. I supported a 580-millimetre design for further assessment, giving up part of the original arrangement. Eleven of sixteen site-fit reviews accepted it and five needed another configuration. The ₹9.6 crore programme did not establish clinical performance, clearance or universal suitability.
For a board, I would make the material assumption and the remaining conditions visible rather than ask directors to choose the equipment dimensions themselves. The case shows why a product-readiness statement needs a defined setting and assessment scope. A smaller number in the specification may address one constraint while leaving others to the appropriate technical, site and quality owners. The oversight question is whether management’s account preserves those limits when explaining the offer and the next decision.
The planned programme covered 240 sites, seventy-two of which had not confirmed prerequisites. We made preinstallation assessment explicit and staged a ninety-unit pilot. Seventy-three units were installed at review and seventeen remained pending. The ₹6.3 crore expense supported the programme without establishing a before-and-after improvement, a patient outcome or a commercial-recognition conclusion.
I would use that experience to ask what a completion statement actually includes and which customer dependencies remain unresolved. Management should explain the work and its owners through the board’s established channels, while finance determines recognition and specialists assess suitability. The board should not be left to discover that a dispatch figure had been used as shorthand for a different outcome. Retaining the pending units supports a more accurate collective understanding even when it makes the progress account less convenient.
My first preparation would be to understand the proposed company’s products, customer settings and governance arrangements. I would review the board’s responsibilities, committee mandates and information flows with the chair and relevant colleagues. An equipment business may have a different clinical, regulatory or service context from Pravellen’s invented examples. I would not assume that familiarity with one product portfolio supplies the necessary understanding of another institution’s obligations.
I would then examine how management describes product scope and material uncertainty. That would include the relationship between customer research, technical assessment, quality and regulatory evidence, commercial commitments and service delivery. I would seek the authorised account through established channels, rather than independently direct site visits or product redesigns. Where a question requires specialist competence, I would identify that need and learn how the board obtains the appropriate evidence.
During the first year, I would ask whether my questions help distinguish a feature claim from a supported customer outcome. I would welcome feedback on relevance and proportionality: a physical constraint may be decisive in one portfolio and immaterial in another. Committee participation would depend on the actual mandate, existing skills and preparation. This account asserts no readiness to chair a specialist committee merely because I have held a senior product role.
Before consideration, I would disclose current employment, relevant customer and supplier relationships, investor links, previous work and personal interests. The company would need to assess those facts through the appropriate process. My stated willingness to exercise judgement cannot establish independence for a particular appointment. I would also clarify which product evidence may be discussed without disclosing restricted drawings, procurement records or information belonging to customers and colleagues.
Twenty-four annual days would be an initial, conditional estimate. Employer agreement, induction, committee work, travel and unusual demands must be evaluated against the intended role. I would revisit that estimate if the responsibilities changed. The fictional website does not provide an appointment clearance or permission to share employer material. A real conversation needs verified experience and an authorised evidence route, with the institution’s assessment remaining distinct from the candidate’s preferred account of their contribution.
No independence determination is made here. Employment, customer, supplier, investor and personal connections would need disclosure and assessment for the intended institution.